ClinicalTrials.Veeva

Find clinical trials for Adenocarcinoma in San Francisco, CA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma
Cancer
Pancreatic Cancer
Colorectal Cancer
Stomach Cancer
Prostatic Cancer
Esophageal Cancer

Adenocarcinoma trials near San Francisco, CA, USA:

Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (REVOLUTION)

to evaluate the safety and efficacy of first-line chemo-immunotherapy combinations in participants with metastatic pancreatic ductal adenocarcinoma...

Active, not recruiting
Metastatic Pancreatic Adenocarcinoma
Drug: Nab-paclitaxel (nP) (Cohort A, B and C)
Drug: Gemcitabine (gem) (Cohort A, B and C)

Phase 1

Cancer Insight

San Francisco, California, United States and 5 other locations

combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC).Two cohorts will be enrolled in parallel in this study:...

Active, not recruiting
Pancreatic Adenocarcinoma
Drug: Fluorouracil
Drug: RO6874281

Phase 1, Phase 2

Roche
Roche

San Francisco, California, United States and 26 other locations

and capecitabine monotherapy in patients with metastatic pancreatic adenocarcinoma whose disease has not progressed on a first line fluoropy...

Enrolling
Metastatic Pancreatic Adenocarcinoma
Drug: Capecitabine
Drug: Ivaltinostat

Phase 1, Phase 2

CG Pharmaceuticals

San Francisco, California, United States and 16 other locations

as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma...

Active, not recruiting
Gastric Adenocarcinoma
Gastric Cancer
Drug: Capecitabine 1000mg/ m2 BID
Drug: DKN-01 600mg

Phase 2

Leap Therapeutics

San Francisco, California, United States and 47 other locations

participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignatur...

Enrolling
Endometrial Adenocarcinoma
Urothelial Carcinoma
Drug: ACR-368
Diagnostic Test: OncoSignature

Phase 1, Phase 2

Acrivon Therapeutics

Palo Alto, California, United States and 66 other locations

mCRPC. Patients enrolled in the Phase 2a portion of the study will have either Small Cell Neuroendocrine Prostate Cancer(SCNC)(Cohort A) or adenocarcinoma...

Active, not recruiting
Small Cell Carcinoma
Neuroendocrine Tumors
Drug: BXCL701 monotherapy
Drug: BXCL701 plus Pembrolizumab

Phase 1, Phase 2

BioXcel Therapeutics

San Francisco, California, United States and 11 other locations

and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma...

Enrolling
Gastroesophageal Junction Cancer
Gastric Cancer
Drug: Apatinib
Drug: Ramucirumab+ paclitaxel

Phase 3

AstraZeneca
AstraZeneca

Santa Rosa, California, United States and 118 other locations

unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Why is this study being done? SPOTLIGHT is a new clinical st...

Active, not recruiting
Metastatic Gastric Adenocarcinoma or Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Drug: placebo
Drug: oxaliplatin

Phase 3

Astellas
Astellas

San Francisco, California, United States and 219 other locations

and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma...

Enrolling
Metastatic Cancer
KRAS Activating Mutation
Drug: avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel

Phase 1, Phase 2

Verastem

San Francisco, California, United States and 10 other locations

This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX). It...

Enrolling
Esophageal Adenocarcinoma
Gastric Adenocarcinoma
Drug: tucatinib
Drug: trastuzumab

Phase 1, Phase 2

Seagen
Seagen

Palo Alto, California, United States and 21 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems